Protein targets of rugulactone and illudin S: An analysis of their function and mechanism of action
胡古内酯和隐球菌素 S 的蛋白质靶点:功能和作用机制分析
基本信息
- 批准号:233925483
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Research Grants
- 财政年份:2012
- 资助国家:德国
- 起止时间:2011-12-31 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Natural products have found use in human medicine for millennia, and to date, most modern medicines are based on natural products. These compounds typically act on multiple protein targets, yet the identity of most of the protein targets for these molecules remains unknown. Identification of the protein targets of bioactive natural products can provide valuable information concerning the mode of action of these molecules, as well as provide inspiration for novel drug targets and lead structures. In this proposal, we describe a multidisciplinary platform for the in depth characterization of illudin S and rugulactone. This platform includes not only the chemoproteomic toolset for target identification but also incorporates downstream methodologies for functional characterization. Illudin S possesses potent and interesting anticancer properties - particularly against multidrug resistant cancer cell lines. While DNA alkylation is likely its primary mechanism of action, the identity of its protein targets in eukaryotic cells remains obscure. These protein targets may contribute to antitumor activity, as well as unwanted toxicity. Application of illudin probes in cellular systems will allow us to identify the protein targets using a mass spectrometry-based proteomic platform. Using this platform, we have previously established ThiD - an essential enzyme in bacterial thiamin biosynthesis- as a target of rugulactone, and we here propose further characterization of ThiD. Structural analysis will reveal the mode of inhibition of ThiD by rugulactone. Functional annotation will be carried out by gene deletion studies and quantitative PCR experiments. These studies will also be applied to the identified targets of the illudins. Moreover, the inhibition of bacterial metabolic pathways is a valuable approach to novel antibacterial targets. For example, the inhibition of bacterial folate biosynthesis is a key target for antibacterial therapy and has been in use for over 60 years. Much like folate (vitamin B9), thiamin (vitamin B1) is an essential cofactor in all living organisms, and while most microorganisms can synthesize thiamine de novo, humans and other animals rely solely on dietary intake to obtain thiamine. Therefore, inhibition of essential enzymes in the thiamine biosynthetic pathway has great potential for much-needed novel antibacterial targets. ThiD has been identified as an in vivo essential enzyme in Mycobacterium tuberculosis (MT), the causative agent for tuberculosis (TB). MT does not contain the genes for thiamine salvage or transport, making this organism entirely dependent on de novo synthesis for this essential vitamin. We propose that the inhibition of MT ThiD represents an attractive target for the discovery and development of novel antitubercular drugs. Using rugulactone as a lead structure for further SAR efforts, we propose to explore the inhibition of MT ThiD and evaluate its use as a novel drug target.
天然产物在人类医学中的应用已有数千年的历史,迄今为止,大多数现代药物都是基于天然产物。 这些化合物通常作用于多个蛋白质靶点,但这些分子的大多数蛋白质靶点的身份仍然未知。生物活性天然产物的蛋白质靶点的鉴定可以提供关于这些分子的作用模式的有价值的信息,以及为新的药物靶点和先导结构提供灵感。在这个建议中,我们描述了一个多学科的平台,深入表征伊鲁丁S和rugulactone。 该平台不仅包括用于靶标鉴定的化学蛋白质组学工具集,还包括用于功能表征的下游方法。Illudin S具有有效和有趣的抗癌特性-特别是针对多药耐药癌细胞系。 虽然DNA烷基化可能是其主要作用机制,但其在真核细胞中的蛋白质靶点的身份仍然不清楚。 这些蛋白质靶标可能有助于抗肿瘤活性以及不需要的毒性。在细胞系统中的应用illudin探针将允许我们使用基于质谱的蛋白质组学平台来识别蛋白质靶点。使用这个平台,我们以前已经建立了ThiD -一种在细菌硫胺素生物合成的必需酶-作为rugulactone的目标,我们在这里提出进一步表征ThiD。结构分析将揭示rugulactone抑制ThiD的模式。通过基因缺失研究和定量PCR实验进行功能注释。这些研究也将应用于确定的目标的伊鲁定。此外,抑制细菌代谢途径是一种有价值的方法,以新的抗菌靶标。 例如,细菌叶酸生物合成的抑制是抗菌治疗的关键靶标,并且已经使用了60多年。与叶酸(维生素B 9)类似,硫胺素(维生素B1)是所有生物体中必不可少的辅助因子,虽然大多数微生物可以从头合成硫胺素,但人类和其他动物仅依赖于饮食摄入来获得硫胺素。因此,抑制硫胺素生物合成途径中的必需酶对于急需的新型抗菌靶标具有巨大的潜力。 ThiD已被鉴定为结核分枝杆菌(MT)(结核病(TB)的病原体)中的体内必需酶。MT不包含硫胺素补救或运输的基因,使这种生物体完全依赖于这种必需维生素的从头合成。我们认为MT ThiD的抑制是发现和开发新型抗结核药物的一个有吸引力的靶点。使用rugulactone作为进一步SAR努力的先导结构,我们建议探索MT ThiD的抑制作用,并评估其作为新型药物靶标的用途。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Human lysosomal acid lipase inhibitor lalistat impairs Mycobacterium tuberculosis growth by targeting bacterial hydrolases
- DOI:10.1039/c6md00231e
- 发表时间:2016-01-01
- 期刊:
- 影响因子:0
- 作者:Lehmann, J.;Vomacka, J.;Sieber, S. A.
- 通讯作者:Sieber, S. A.
A subfamily of bacterial ribokinases utilizes a hemithioacetal for pyridoxal phosphate salvage.
细菌核激酶亚家族利用半硫缩醛来回收磷酸吡哆醛
- DOI:10.1021/ja411785r
- 发表时间:2014
- 期刊:
- 影响因子:15
- 作者:Nodwell;Schneider;Sieber
- 通讯作者:Sieber
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Professor Dr. Stephan A. Sieber其他文献
Professor Dr. Stephan A. Sieber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Professor Dr. Stephan A. Sieber', 18)}}的其他基金
Exploiting quorum sensing inhibition of the natural products fimbrolide and elegaphenone in gram-negative bacteria
利用群体感应抑制革兰氏阴性菌中的天然产物芬溴内酯和榄香酮
- 批准号:
358921956 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Research Grants
Chemical-proteomic tools to monitor pyridoxal phosphorylation and its function as an enzyme cofactor in disease-related pathways
用于监测吡哆醛磷酸化及其作为疾病相关途径中酶辅因子的功能的化学蛋白质组学工具
- 批准号:
314976069 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Research Grants
Identification of chemical compounds to inhibit the caseinolytic protease ClpXP complex and evaluate their biological activity
抑制酪蛋白分解酶 ClpXP 复合物的化合物的鉴定并评估其生物活性
- 批准号:
282324388 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Research Grants
A chemical proteomic strategy to identify novel drug targets in Plasmodium falciparum and corresponding lead compounds for the development of new antimalarials
一种化学蛋白质组学策略,用于识别恶性疟原虫中的新药物靶标和相应的先导化合物,用于开发新型抗疟药
- 批准号:
192524457 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Research Grants
Identification, validation and functional characterization of targets of myxobacterial compounds with potential for pharmacological cancer treatment
具有药物癌症治疗潜力的粘细菌化合物靶标的鉴定、验证和功能表征
- 批准号:
187769183 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Research Units
Chemisch-proteomische Strategien zur Identifikation krankheitsassoziierter Enzyme in pathogenen Bakterien als neuartige Angriffsziele für Antibiotika
化学蛋白质组学策略识别病原菌中与疾病相关的酶作为抗生素的新靶标
- 批准号:
28198381 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Independent Junior Research Groups
A Proteomic Strategy for Inhibiting Cancer-Associated Enzymes
抑制癌症相关酶的蛋白质组学策略
- 批准号:
5438978 - 财政年份:2004
- 资助金额:
-- - 项目类别:
Emmy Noether International Fellowships
Deciphering the structure activity relationship, mode of action and uptake of isonitrile antibiotics in Gram-negative bacteria
破译革兰氏阴性菌中异腈抗生素的结构活性关系、作用方式和摄取
- 批准号:
505074737 - 财政年份:
- 资助金额:
-- - 项目类别:
Research Grants
相似国自然基金
miR-29a "targets" PPAR δ对心力衰竭的作用及作为潜在标志物的研究
- 批准号:81371895
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
相似海外基金
HMA domain proteins as conserved targets of pathogens that exploit plasmodesmata
HMA 结构域蛋白作为利用胞间连丝的病原体的保守靶标
- 批准号:
BB/X016056/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Collaborative R&D
Developmental mechanisms specifying vagal innervation of organ targets
指定器官目标迷走神经支配的发育机制
- 批准号:
10752553 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Finding the targets of natural products in complex botanical extracts.
寻找复杂植物提取物中天然产物的靶标。
- 批准号:
LP230100225 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Linkage Projects
Four-stranded fungal fatality: Unveiling G-quadruplexes as future antifungal targets
四链真菌死亡:揭示 G-四链体作为未来抗真菌靶点
- 批准号:
BB/Y005058/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Preclinical validation of synthetic biomolecules to treat Breast Cancer from AI-enabled discovery of novel lncRNA therapeutic targets.
通过人工智能发现新型 lncRNA 治疗靶点,对合成生物分子治疗乳腺癌进行临床前验证。
- 批准号:
10110204 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Launchpad
Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma
利用患者主导的遗传学来确定转移性胆管癌的新治疗靶点
- 批准号:
EP/Y028546/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Breaking the Barrier: Mapping protein interactions in the bacterial outer membrane as targets for new antimicrobials
打破障碍:绘制细菌外膜中的蛋白质相互作用作为新抗菌药物的目标
- 批准号:
MR/Y012453/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Identifying novel & repurposing drug targets for Atrial Fibrillation MEDicines
识别小说
- 批准号:
EP/Z000211/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Develop the novel targets and immunotherapy-combination agents through targeting nuclear transport receptor
以核转运受体为靶点开发新靶点和免疫治疗联合药物
- 批准号:
24K13116 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)